About OncoOne – our Team and our Vision

United in developing breakthrough cancer therapeutics

Cancer remains a leading cause of death worldwide, accounting for nearly 10 million lives taken in 2020, or nearly one in six deaths (WHO, International Agency for Research on Cancer). Although new therapies have demonstrated success in treating this widespread disease, critical and urgent issues including the development of resistance mechanisms, off-target cytotoxicity and lack of efficacy remain.

In an effort to contribute to the global fight against cancer, OncoOne is leveraging our proprietary drug development know-how to create first-in-class, novel, and highly potent therapeutics in order to treat underserved patients suffering from solid tumor cancers.

As a business model, OncoOne intends to ensure that we strive to apply state-of-the-art technologies and the highest possible quality standards in order to continue growing a successful and continuously evolving life science company.

Onco One - Founders and Management Board - Goal: Develop breakthrough cancer therapeutics for solid tumors

Our Founders & Management Board

The Pioneers of oxMIF

OncoOne was founded in June 2018 by Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl. Our founders have a long history in industrial drug development and oncology research. Each member of the management team has successfully contributed to the development of GMP-grade drug substances, patents and scientific publications. Our management team is comprised of professionals experienced in science management, leading networks of innovation by external collaborations and performing first-class in-house laboratory work.

OncoOne’s leadership team discovered that the macrophage migration inhibitory factor (MIF) oxidized at sites of inflammation, such as a tumor, arthritic joint, or asthmatic lung. They discovered and named this disease-related isoform of MIF the oxidized migration inhibitory factor (oxMIF) and together with the rest of the OncoOne team are working on first- and best-in-class therapeutics targeting this well-researched cytokine.

OncoOne_Randolf_Kerschbaumer_ PhD
Randolf Kerschbaumer, PhD

Co-Founder &
Chief Executive Officer

Michael Thiele, PhD

Co-Founder &
Chief Scientific Officer

Alexander Schinagl, PhD

Co-Founder &
Chief Technology Officer

Brent Meadows

OncoOne US Co-Founder and
Chief Business Officer

Our team is highly committed to our shared goal of developing breakthrough cancer therapeutics. As our company continues to grow, we are looking for individuals with a passion for science who want to join our team and bring new solutions to underserved indications.

Scientific Advisory Board

Prof. Michael Freissmuth M.D.

Director Center of Physiology & Pharmacology at Medical University Vienna

Prof. Dirk Jäger M.D.

Managing Director National Center for Tumor Diseases (NCT) Heidelberg

Prof. Florian Rüker M.D.

Deputy Head Department of Biotechnology University of Natural Resources and Life Sciences Vienna

Prof. Seamas Donnelly, M.D.

Professor & Head of Medicine at the Trinity College Dublin and Hon. Professor in Translational Medicine of the University of Edinburgh.

Prof. Jennifer Guerriero, Ph.D.

Assistant Professor, Harvard Medical School and Director of the Breast Tumor lmmunology Laboratory at the Dana Farber Cancer Institute.

Prof. Robert A. Mitchell, M.D.

Professor in the Department of Surgery and a member of the Division of lmmunotherapy at the University of Louisville.

Head offices
in Boston (USA) and Vienna (Austria)

a diverse team across the globe with a united mission